AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-22. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
The reaction of endo-Tropacocaine [19145-60-9] (1) with 2,2,2-Trichloroethyl chloroformate (Troc group) [17341-93-4] (2) gave the urethane PC11463908 (3). Reduction with zinc in acetic acid afforded the nortropane, PC11458897 (4). Protection of the secondary amine with Boc anhydride gave PC66624775 (5). Saponification of the ester in potassium hydroxide gave PC11160507 (6). Mitsunobu reaction with 7-hydroxy-3-methoxy-chromen-2-one (Methoxy-Umbelliferon) [68287-05-8] (7) occurred with inversion of stereochemistry from the endo to the exo position, PC89405050 (8). Acid hydrolysis of the Boc protecting group completed the synthesis of pudafensine (9).
When a silicone breast implant ruptures it usually does not deflate, yet the filler gel does leak from it, which can migrate to the implant pocket; therefore, an intracapsular rupture (in-capsule leak) can become an extracapsular rupture (out-of-capsule leak), and each occurrence is resolved by explantation. Although the leaked silicone filler-gel can migrate from the chest tissues to elsewhere in the woman's body, most clinical complications are limited to the breast and armpit areas, usually manifested as granulomas (inflammatory nodules) and axillary lymphadenopathy (enlarged lymph glands in the armpit area). The suspected mechanisms of breast implant rupture are:
== Preparation == Tris is prepared industrially by the exhaustive condensation of nitromethane with formaldehyde under basic conditions (i.e. repeated Henry reactions) to produce the intermediate (HOCH2)3CNO2, which is subsequently hydrogenated to give the final product.
F number is a correlation number used in the analysis of polycyclic aromatic hydrocarbons (PAHs) as a descriptor of their hydrophobicity and molecular size. It was proposed by Robert Hurtubise and co-workers in 1977.
== Legal status == Japan was the first country that allowed the use of sucrose esters as food additives. The Japanese Ministry of Health and Welfare approved sucrose esters in 1959. Then, in 1969, FAO/WHO approved the use of sucrose esters. Sucrose esters were approved and registered by European Food Safety Authority or EFSA under the E number of E 473. In the US, sucrose esters were approved by the FDA (Food and Drug Administration).
Sources: en.wikipedia.org
== Selected books == J.W. Steed, D.R. Turner, K. Wallace Core Concepts in Supramolecular Chemistry and Nanochemistry (Wiley, 2007) 315p. ISBN 978-0-470-85867-7 Brechignac C., Houdy P., Lahmani M. (Eds.) Nanomaterials and Nanochemistry (Springer, 2007) 748p. ISBN 978-3-540-72993-8 H. Watarai, N. Teramae, T. Sawada Interfacial Nanochemistry: Molecular Science and Engineering at Liquid-Liquid Interfaces (Nanostructure Science and Technology) 2005. 321p. ISBN 978-0-387-27541-3 Ozin G., Arsenault A.C., Cademartiri L. Nanochemistry: A Chemical Approach to Nanomaterials 2nd Eds. (Royal Society of Chemistry, 2008) 820p. ISBN 978-1847558954 Kenneth J. Klabunde; Ryan M. Richards, eds. (2009). Nanoscale Materials in Chemistry (2nd ed.). Wiley. ISBN 978-0-470-22270-6.
== Structure == Osteocytes have a stellate shape, approximately 7 micrometers deep and wide by 15 micrometers in length. The cell body varies in size from 5–20 micrometers in diameter and contain 40–60 cell processes per cell, with a cell to cell distance between 20–30 micrometers. A mature osteocyte contains a single nucleus that is located toward the vascular side and has one or two nucleoli and a membrane. The cell also exhibits a reduced size endoplasmic reticulum, Golgi apparatus and mitochondria, and cell processes that radiate largely towards the bone surfaces in circumferential lamellae, or towards a haversian canal and outer cement line typical of osteons in concentric lamellar bone. Osteocytes form an extensive lacunocanalicular network within the mineralized collagen type I matrix, with cell bodies residing within lacunae, and cell/dendritic processes within channels called canaliculi.
In 2013 for the population aged 40-80 years, the global prevalence of glaucoma was estimated at 3.54%, thus affecting 64.3 million worldwide. The same year, 2.97 million people in North America had open-angle glaucoma. By 2040, the prevalence of all types of glaucoma was projected to increase to 111.82 million worldwide and to 4.72 million in North America. Globally, glaucoma is the second-leading cause of blindness, while cataracts are a more common cause. In the United States, glaucoma is a leading cause of blindness for African Americans, who have higher rates of primary open-angle glaucoma, and Hispanic Americans. Bilateral vision loss can negatively affect mobility and interfere with driving. A meta-analysis published in 2009 found that people with primary open-angle glaucoma do not have increased mortality rates or increased risk of cardiovascular death. A 2024 JAMA Ophthalmology article reports that in 2022, an estimated 4.22 million people in the U.S. had glaucoma, with 1.49 million experiencing vision impairment due to the condition, according to a meta-analysis. The study found that Black adults were about twice as likely to be affected by glaucoma as White adults. Glaucoma prevalence was 1.62% among individuals aged 18 and older and 2.56% among those aged 40 and older, while vision-affecting glaucoma occurred in 0.57% and 0.91% of these age groups, respectively.
== Synthesis == 4-Hydroxynonenal is generated in the oxidation of lipids containing polyunsaturated omega-6 fatty acids, such as arachidonic and linoleic acids, and of their 15-lipoxygenase metabolites, namely 15-hydroperoxyeicosatetraenoic and 13-hydroperoxyoctadecadienoic acids. Although they are the most studied ones, in the same process other oxygenated α,β-unsaturated aldehydes (OαβUAs) are generated also, which can also come from omega-3 fatty acids, such as 4-oxo-trans-2-nonenal, 4-hydroxy-trans-2-hexenal, 4-hydroperoxy-trans-2-nonenal and 4,5-epoxy-trans-2-decenal.
The aristocracy and gentry of Calabria, through generally not ideologically Fascist, saw the regime as a force for order and stability, and supported the dictatorship. The prefects and the policemen of Calabria were conservatives who saw themselves as serving King Victor Emmanuel III first and Mussolini second, but supported Fascism over Socialism and Communism and persecuted anti-Fascists. Traditional elites in Calabria joined the Fascist Party, and local branches of Fascist Party were characterized by jostling for power and influence between elite families. In spite of this, conditions in Calabria under the Fascist regime did not improve, as evidenced by surveys conducted by meridionalists (and antifascists) Umberto Zanotti Bianco and Manlio Rossi Doria in 1928 and reported in Tra la perduta gente, which analyzed the social and economic conditions of Africo, a village in Aspromonte that was ruined by the 1908 earthquake and geographically isolated. It was plagued by disease, infant mortality and taxation, lacked a doctor and school (classes were held in the teacher's bedroom), while the inhabitants ate bread from lentils and chickpeas. The government attempted to maintain the rural character of the country, introducing restrictions and disincentives to peasants and laborers to move to the city. Urban areas still developed, as demonstrated by the Grande Reggio project. The first Reggio podestà, Giuseppe Genoese Zerbi. pushed urban expansion and amalgamation.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.